Tafenoquine for the radical cure and prevention of malaria: the importance of testing for G6PD deficiency

doi:10.5694/mja2.50474

. 2020 Mar;212(4):152-153.e1.

doi: 10.5694/mja2.50474. Epub 2020 Feb 9.

Tafenoquine for the radical cure and prevention of malaria: the importance of testing for G6PD deficiency

Robert J Commons^{1

2

3}, James S McCarthy^{4

5}, Ric N Price^{1

6

7}

Affiliations

¹ Menzies School of Health Research, Darwin, NT.
² WorldWide Antimalarial Resistance Network, Darwin, NT.
³ Ballarat Health Services, Ballarat, VIC.
⁴ QIMR Berghofer Medical Research Institute, Brisbane, QLD.
⁵ University of Queensland, Brisbane, QLD.
⁶ Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
⁷ Mahidol University, Bangkok, Thailand.

PMID: 32036613
PMCID: PMC7064913
DOI: 10.5694/mja2.50474

Tafenoquine for the radical cure and prevention of malaria: the importance of testing for G6PD deficiency

Robert J Commons et al. Med J Aust. 2020 Mar.

. 2020 Mar;212(4):152-153.e1.

doi: 10.5694/mja2.50474. Epub 2020 Feb 9.

Authors

Robert J Commons^{1

2

3}, James S McCarthy^{4

5}, Ric N Price^{1

6

7}

Affiliations

¹ Menzies School of Health Research, Darwin, NT.
² WorldWide Antimalarial Resistance Network, Darwin, NT.
³ Ballarat Health Services, Ballarat, VIC.
⁴ QIMR Berghofer Medical Research Institute, Brisbane, QLD.
⁵ University of Queensland, Brisbane, QLD.
⁶ Centre for Tropical Medicine and Global Health, Nuffield Department of Clinical Medicine, University of Oxford, Oxford, UK.
⁷ Mahidol University, Bangkok, Thailand.

PMID: 32036613
PMCID: PMC7064913
DOI: 10.5694/mja2.50474

No abstract available

Keywords: Anti-infective agents; Malaria.

PubMed Disclaimer

Conflict of interest statement

Ric Price is a Wellcome Trust Senior Fellow in Clinical Science (200909).

Ric Price was on the expert panel for the tafenoquine licensing application at the US Federal Drug Administration and on the expert committee for the Australian Therapeutic Goods Administration. His travel expenses to the US were reimbursed by GlaxoSmithKline. James McCarthy received funding from 60 Degrees Pharmaceuticals to conduct a randomised controlled trial to test the activity of tafenoquine as a potential drug for the chemoprophylaxis of malaria.

Cited by

Field assessment of the operating procedures of a semi-quantitative G6PD Biosensor to improve repeatability of routine testing.
Sadhewa A, Chaudhary A, Panggalo LV, Rumaseb A, Adhikari N, Adhikari S, Rijal KR, Banjara MR, Price RN, Thriemer K, Ghimire P, Ley B, Satyagraha AW. Sadhewa A, et al. PLoS One. 2024 Jan 19;19(1):e0296708. doi: 10.1371/journal.pone.0296708. eCollection 2024. PLoS One. 2024. PMID: 38241389 Free PMC article.
Cytochrome P450 2D6 profiles and anti-relapse efficacy of tafenoquine against Plasmodium vivax in Australian Defence Force personnel.
Dowd S, Chen N, Gatton ML, Edstein MD, Cheng Q. Dowd S, et al. Antimicrob Agents Chemother. 2023 Dec 14;67(12):e0101423. doi: 10.1128/aac.01014-23. Epub 2023 Nov 16. Antimicrob Agents Chemother. 2023. PMID: 37971260 Free PMC article.
Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis.
Mehdipour P, Rajasekhar M, Dini S, Zaloumis S, Abreha T, Adam I, Awab GR, Baird JK, Brasil LW, Chu CS, Cui L, Daher A, do Socorro M Gomes M, Gonzalez-Ceron L, Hwang J, Karunajeewa H, Lacerda MVG, Ladeia-Andrade S, Leslie T, Ley B, Lidia K, Llanos-Cuentas A, Longley RJ, Monteiro WM, Pereira DB, Rijal KR, Saravu K, Sutanto I, Taylor WRJ, Thanh PV, Thriemer K, Vieira JLF, White NJ, Zuluaga-Idarraga LM, Guerin PJ, Price RN, Simpson JA, Commons RJ; WWARN Vivax Adherence Study Group. Mehdipour P, et al. Malar J. 2023 Oct 10;22(1):306. doi: 10.1186/s12936-023-04725-w. Malar J. 2023. PMID: 37817240 Free PMC article.
Population screening for glucose-6-phosphate dehydrogenase deficiency using quantitative point-of-care tests: a systematic review.
Zailani MAH, Raja Sabudin RZA, Ithnin A, Alauddin H, Sulaiman SA, Ismail E, Othman A. Zailani MAH, et al. Front Genet. 2023 Jun 14;14:1098828. doi: 10.3389/fgene.2023.1098828. eCollection 2023. Front Genet. 2023. PMID: 37388931 Free PMC article.
Plasmodium vivax in Children: Hidden Burden and Conspicuous Challenges, a Narrative Review.
Drysdale M, Tan L, Martin A, Fuhrer IB, Duparc S, Sharma H. Drysdale M, et al. Infect Dis Ther. 2023 Jan;12(1):33-51. doi: 10.1007/s40121-022-00713-w. Epub 2022 Nov 15. Infect Dis Ther. 2023. PMID: 36378465 Free PMC article. Review.

See all "Cited by" articles

References

1. Baird JK. Primaquine toxicity forestalls effective therapeutic management of the endemic malarias. Int J Parasitol 2012; 42: 1049–1054. - PubMed
1. Baird JK. Tafenoquine for travelers’ malaria: evidence, rationale and recommendations. J Travel Med 2018; 25: tay100. - PMC - PubMed
1. Brueckner RP, Lasseter KC, Lin ET, Schuster BG. First‐time‐in‐humans safety and pharmacokinetics of WR 238605, a new antimalarial. Am J Trop Med Hyg 1998; 58: 645–649. - PubMed
1. Llanos‐Cuentas A, Lacerda MV, Rueangweerayut R, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double‐blind, randomised, phase 2b dose‐selection study. Lancet 2014; 383: 1049–1058. - PubMed
1. Chu CS, Freedman DO. Tafenoquine and G6PD: A Primer for Clinicians. J Travel Med 2019; 26: taz023. - PMC - PubMed

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions

Grants and funding

200909/Z/16/Z/WT_/Wellcome Trust/United Kingdom

LinkOut - more resources

Full Text Sources
Medical
- Genetic Alliance
- MedlinePlus Health Information
Miscellaneous
- NCI CPTAC Assay Portal

[1] Baird JK. Primaquine toxicity forestalls effective therapeutic management of the endemic malarias. Int J Parasitol 2012; 42: 1049–1054. - PubMed

[2] Baird JK. Primaquine toxicity forestalls effective therapeutic management of the endemic malarias. Int J Parasitol 2012; 42: 1049–1054. - PubMed

[3] Baird JK. Tafenoquine for travelers’ malaria: evidence, rationale and recommendations. J Travel Med 2018; 25: tay100. - PMC - PubMed

[4] Baird JK. Tafenoquine for travelers’ malaria: evidence, rationale and recommendations. J Travel Med 2018; 25: tay100. - PMC - PubMed

[5] Brueckner RP, Lasseter KC, Lin ET, Schuster BG. First‐time‐in‐humans safety and pharmacokinetics of WR 238605, a new antimalarial. Am J Trop Med Hyg 1998; 58: 645–649. - PubMed

[6] Brueckner RP, Lasseter KC, Lin ET, Schuster BG. First‐time‐in‐humans safety and pharmacokinetics of WR 238605, a new antimalarial. Am J Trop Med Hyg 1998; 58: 645–649. - PubMed

[7] Llanos‐Cuentas A, Lacerda MV, Rueangweerayut R, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double‐blind, randomised, phase 2b dose‐selection study. Lancet 2014; 383: 1049–1058. - PubMed

[8] Llanos‐Cuentas A, Lacerda MV, Rueangweerayut R, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double‐blind, randomised, phase 2b dose‐selection study. Lancet 2014; 383: 1049–1058. - PubMed

[9] Chu CS, Freedman DO. Tafenoquine and G6PD: A Primer for Clinicians. J Travel Med 2019; 26: taz023. - PMC - PubMed

[10] Chu CS, Freedman DO. Tafenoquine and G6PD: A Primer for Clinicians. J Travel Med 2019; 26: taz023. - PMC - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Tafenoquine for the radical cure and prevention of malaria: the importance of testing for G6PD deficiency

Affiliations

Tafenoquine for the radical cure and prevention of malaria: the importance of testing for G6PD deficiency

Authors

Affiliations

Conflict of interest statement

Similar articles

Cited by

References

MeSH terms

Substances

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous

Conflict of interest statement

Similar articles

Cited by

References

MeSH terms

Substances

Related information

Grants and funding

LinkOut - more resources

Full Text Sources

Medical

Miscellaneous